Effect of short term recombinant human erythropoietin (rHuEPO) therapy in the prevention of anemia of prematurity (AOP) in very low birth weight (VLBW) neonates

Yasmeen, B H Nazma; Chowdhury, Mak Azad; Hoque, MM; Hossain, Mohammad Monir; Jahan, Rowshan; Akhtar, Shazieya

doi:10.3329/bmrcb.v38i3.14340

Cited by 8 publications

(5 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As plasma erythropietin (EPO) levels are relatively low in preterm infants, it is rational to consider rHuEPO as a potential treatment for anemia 28 29 30 . However, rHuEPO has not been widely used in NICU because of its uncertain efficacy 31 32 33 34 . Early use of supplemental of iron may probably reduce the incidence of anemia, however, the optimal dose and time of iron supplementation remains unclear and needs further research 35 .…”

Section: Discussionmentioning

confidence: 99%

Association between anemia and bronchopulmonary dysplasia in preterm infants

Duan

Kong

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Anemia is commonly seen in preterm infants. It may reduce the capacity of hemoglobin to transport oxygen throughout the body and may result in tissue and organ dysfunction. This study aimed to investigate the effect of anemia on the development of bronchopulmonary dysplasia (BPD) in preterm infants. 243 infants who were admitted to BaYi Children’s Hospital Affiliated to Clinical Medical College in Beijing Military General Hospital with gestational age (GA) less than 32 weeks from February, 2014 to February, 2015 were included in the study. Maternal and infant data were recorded. Multivarariate logistic regression analysis was performed to determine the association between anemia and BPD. Of 243 preterm infants, the incidence of anemia was higher in BPD patients than non-BPD patients (p < 0.001). Mean Hct in BPD patients was lower than non-BPD patients at different time points in 1d, 7d, 14d, and 21d. Controlling for other confounding factors, early anemia was associated with an increased risk of BPD. Number of transfusions is also a significant risk factor for BPD (p = 0.001). Therefore, prevention and treatment of early anemia is necessary and reducing number of transfusions may reduce the incidence of BPD in preterm infants.

show abstract

Section: Discussionmentioning

confidence: 99%

Association between anemia and bronchopulmonary dysplasia in preterm infants

Duan

Kong

et al. 2016

Sci Rep

View full text Add to dashboard Cite

show abstract

“…However, in a research by Pasha et al, 42 oral EPO was used for the treatment of anemia of prematurity, and the results reflected an increase in the plasma level of EPO in the EPOtreated group. Also, Yasmeen et al 43 stated that the use of EPO in infants could lead to increase in hematocrit and a decrease in the frequency of transfusion required for these newborns. Romagnoli et al 44 in their study examined the effect of EPO on the retinopathy of preterm infants.…”

Section: Discussionmentioning

confidence: 99%

The effects of enteral artificial amniotic fluid-containing erythropoietin on short term outcomes of preterm infants

et al. 2019

View full text Add to dashboard Cite

Necrotizing Enterocolitis (NEC) is a common devastating gastrointestinal disease, which usually develops in premature infants. Erythropoietin (EPO) as a hematopoietic hormone produced by the kidney can also be naturally found in amniotic fluid and breast milk. There is some evidence that supports the contribution of EPO in the prevention of inflammation and intestinal tissue repair. This study was aimed to determine if oral administration of artificial amniotic fluid with or without EPO would protect preterm infants against NEC and improve the certain neonatal outcomes. In this study, 150 preterm infants with gestational age 28 weeks or less and birth weight 1250 grams or less were enrolled. The infants were divided randomly into 3 groups: 1) Control group (n=50) with routine feeding protocol without any administration; 2) Amniotic fluid group (n=50) with 5mL/kg synthetic amniotic fluid; 3) EPO group (n=50) with RhuEPO dissolved in the synthetic amniotic fluid. The administrations of the study solution were started 3 days after the birth and were continued for 3 weeks (21 days). The infants in the study groups were followed up until discharge and the frequency of NEC, mortality, and other complications of the disease among the groups were compared. The mortality rate in preterm infants of the amniotic fluid and EPO groups were significantly lower than in the control group (p=0.027). We couldn't find any significant differences in the frequency of NEC and other complications among the three study groups. The administration of synthetic amniotic fluid (with or without EPO) in preterm infants may decrease the mortality rate. Use of EPO in synthetic amniotic fluid did not affect the frequency of NEC.

show abstract

“…5 Such losses typically result in multiple RBC transfusions. This iatrogenic anaemia is commonly followed byAOP, necessitating additional transfusions.…”

Section: Discussionmentioning

confidence: 99%

“…Babies with gestational age <34 weeks, having birth weight<1500 gm, with stable cardiopulmonary status and oral feeding has been started with breast milk and an amount of at least 50 ml/kg/day is achieved, has been included. 5 Infants with congenital anomalies, intra-ventricular hemorrhage, neonatal seizures, immune-mediated hemolytic anemia or having evidence of acquired or congenital infection or babies requiring ventilator support were excluded. After enrollment of each newborn, group allocation was done with sealed envelope method in to three groups' 20 each.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Effect of Oral Erythropoietin in Prevention of Anemia of Prematurity

Alam¹,

Khan

Nahar

et al. 2018

Bangladesh J Child Health

View full text Add to dashboard Cite

Introduction: Anemia of prematurity (AOP) is a common problem of very low birth weight babies. Blood transfusion is a necessity when it occurs in moderate to Methods: This randomized controlled study conducted in the NICU of BSMMU over one year. Total 60 preterm (<34 weeks)VLBW (<1500g) infants were enrolled and randomly divided into Control (group-I), Oral (group-II) and Subcutaneous (group III). Experimental groups (group-II & group-III) received rhEPO 400 IU/Kg, 3 times weekly in oral and subcutaneous (S/C) route respectively and continued for 2 weeks (Total 6 doses). Therapy was initiated 14 days after birth when the baby achieved oral feeding of at least 50 ml/kg/day of breast milk. All infants received oral iron and folic acid

show abstract

Effect of short term recombinant human erythropoietin (rHuEPO) therapy in the prevention of anemia of prematurity (AOP) in very low birth weight (VLBW) neonates

Cited by 8 publications

References 16 publications

Association between anemia and bronchopulmonary dysplasia in preterm infants

Association between anemia and bronchopulmonary dysplasia in preterm infants

The effects of enteral artificial amniotic fluid-containing erythropoietin on short term outcomes of preterm infants

Effect of Oral Erythropoietin in Prevention of Anemia of Prematurity

Contact Info

Product

Resources

About